Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eyevensys SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11262
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS-609, is a device-plasmid combination method to express anti-VEGF compound for treating age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME); and EYS-611 for retinal degeneration. Eyevensys’ EyeCET platform is a non-viral technology utilizing ETIS (Electro-Transfection Injection System) device to deliver plasmids encoding for the production therapeutic proteins in the ciliary muscle. The company works in partnership with organizations such as Eurogentec, Declic, Fesys and CytoxLab to validate its platform technology. Eyevensys is headquartered in Paris, France.

Eyevensys SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eyevensys SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS – Key Competitors 15
Eyevensys SAS – Key Employees 16
Eyevensys SAS – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Dec 12, 2017: Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer 18
Sep 04, 2017: Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer 19
Mar 21, 2017: Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman 20
Product News 21
05/09/2017: Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases 21
04/20/2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development 22
04/11/2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Eyevensys SAS, Pharmaceuticals & Healthcare, Key Facts 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eyevensys Raises Additional Funds in Series A Financing 11
Eyevensys Secures Venture Funding 12
Eyevensys Raises Funds In Second Round Of Financing 13
Eyevensys Raises US$2 Million In First Round Of Financing 14
Eyevensys SAS, Key Competitors 15
Eyevensys SAS, Key Employees 16

List of Figures
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eyevensys SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eyevensys SAS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Life Time Fitness, Inc:企業の戦略・SWOT・財務分析
    Life Time Fitness, Inc - Strategy, SWOT and Corporate Finance Report Summary Life Time Fitness, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Alpiq Holding AG (ALPH)-エネルギー分野:企業M&A・提携分析
    Summary Alpiq Holding AG (Alpiq) is an independent energy services company. The company produces electricity; and carries out energy trading and energy sales. It generates energy from hydro, nuclear, coal, natural gas, wind, and solar sources. Alpiq offers energy services for buildings and plants, a …
  • Wartsila Corp (WRT1V):電力:M&Aディール及び事業提携情報
    Summary Wartsila Corp (Wartsila) is a mechanical or industrial engineering company. It offers smart technologies and complete lifecycle solutions. Through sustainable innovation, total efficiency, and data analytics, the company harnesses the environmental and economic performance of the vessels and …
  • CUNA Mutual Group:企業の戦略・SWOT・財務情報
    CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report Summary CUNA Mutual Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Usg Corporation
    Usg Corporation - Strategy, SWOT and Corporate Finance Report Summary Usg Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Taiga Building Products Ltd (TBL):企業の戦略的SWOT分析
    Taiga Building Products Ltd (TBL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Forge Energy LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Forge Energy LLC (Forge Energy) is an independent oil and gas exploration and production company that acquires, explores, operates, manages, produces and develops natural oil and gas properties. The company offers services such as consolidation, acquisition, leasing, and exploitation of matu …
  • Kootenai Electric Cooperative, Inc.:発電所・企業SWOT分析
    Kootenai Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Apple Inc:企業の戦略・SWOT・財務分析
    Apple Inc - Strategy, SWOT and Corporate Finance Report Summary Apple Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Kerr Corp:企業の戦略的SWOT分析
    Kerr Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Avangrid Renewables LLC:電力:M&Aディール及び事業提携情報
    Summary Avangrid Renewables LLC (Avangrid Renewables) a subsidiary of Avangrid Renewables Holdings, Inc., is a renewable energy company that carries out electricity generation from renewable energy sources including wind, biomass, solar energy and thermal energy. The company also provides services s …
  • Bluestar Adisseo Co (600299):企業の財務・戦略的SWOT分析
    Summary Bluestar Adisseo Co (Bluestar Adisseo), a subsidiary of China National BlueStar (Group) Co Ltd, is a chemical company that offers research, development, production and sales of feed additives. The company offers functional products, special products and others. It provides methionine product …
  • Koken Co Ltd:企業の戦略的SWOT分析
    Koken Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • California Cryobank-製薬・医療分野:企業M&A・提携分析
    Summary California Cryobank (CCB) is a healthcare service provider that offers reproductive, stem cell and donor selection services. The center offers services such as donor semen, pricing, donor information subscriptions, graduate donors, donor information, consultation services, genetic services, …
  • CareDx Inc (CDNA):医療機器:M&Aディール及び事業提携情報
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • Hoosier Energy Rural Electric Cooperative, Inc.:企業の発電所・SWOT分析2018
    Hoosier Energy Rural Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, …
  • Thales USA, Inc.:戦略・SWOT・企業財務分析
    Thales USA, Inc. - Strategy, SWOT and Corporate Finance Report Summary Thales USA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cellnovo Ltd-医療機器分野:企業M&A・提携分析
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management system, including an insulin patch pump, activity monitor, cellular-enabled wireless touchscreen handset with integrated bl …
  • Hangzhou Tigermed Consulting Co Ltd (300347):企業の財務・戦略的SWOT分析
    Summary Hangzhou Tigermed Consulting Co Ltd (Tigermed) is a contract research organization (CRO) that provides clinical trial services. It offers regulatory submission and approval, medical translation and GMP (Good Manufacturing Practice) consulting, medical monitoring, project management, medical …
  • Pembina Pipeline Corp (PPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Pembina Pipeline Corp (Pembina) is a midstream oil and gas company. It owns and operates an integrated system of pipelines that transports hydrocarbon liquids such as conventional crude oil, heavy oil, synthetic crude oil, and oil sands products. The company offers services such as oil and n …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆